Drug
Tafolecimab clinical trials
Also written IBI306.
- studies test it
- 17
- open now
- 8
- in phase 3
- 7
- first study started
- 2017
Keep track of what changes. Save the tafolecimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
16 studies that test it; most in 2019 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 7
- Phase 3
- 7
- Phase 4
- 1
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 9
Innovent Biologics (Suzhou) Co. Ltd. (8) · Beijing Tiantan Hospital (1) · Guangdong Provincial People's Hospital (1) · The Affiliated Hospital of Xuzhou Medical University (1) · China National Center for Cardiovascular Diseases (1) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)
Often tested with
Tested in the same studies.
Sintilimab (2) · Sitagliptin (1) · Zeprumetostat (1) · Ursodeoxycholic Acid (1)
Studies
Open first, then newest update. How each study uses tafolecimab is read from its arms, and is right about nine times in ten.
Testing it · 17
- INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)Not yet recruitingNot applicableBeijing Tiantan HospitalNCT07341958Written as Tafolecimab
- Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon CancerRecruitingPhase 2Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityNCT07840677Written as Tafolecimab
- Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung CancerRecruitingPhase 2Second Affiliated Hospital, Zhejiang University, School of MedicineNCT07061535Written as Tafolecimab
- Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder CancerRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07717242Written as Tafolecimab
- Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled TrialNot yet recruitingPhase 3Guangdong Provincial People's HospitalNCT07686796Written as Tafolecimab
- Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction PatientsNot yet recruitingPhase 4The Affiliated Hospital of Xuzhou Medical UniversityNCT06683131Written as Tafolecimab
- A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.RecruitingPhase 2Jinghui WangNCT06421298Written as Tafolecimab
- Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese PopulationNot yet recruitingNot applicableChina National Center for Cardiovascular DiseasesNCT06096909Written as Tafolecimab
- IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed HyperlipidemiaActive, not recruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07473960Written as IBI306
- A Study of IBI306 in Participants With HypercholesterolemiaCompletedPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT04709536Written as IBI306
- Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With HypercholesterolemiaCompletedPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT03815812Written as IBI306
- Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male VolunteersCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05792917Written as tafolecimab (a modified manufacturing process)
- Safety and Efficacy of IBI306 in HeFH PatientsCompletedPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT04179669Written as IBI306
- A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial HypercholesterolemiaCompletedPhase 2/3Innovent Biologics (Suzhou) Co. Ltd.NCT04031742Written as IBI306
- Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial HypercholesterolemiaCompletedPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT04289285Written as IBI306 450mg SC Q4W
- Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial HypercholesterolemiaStatus unknownPhase 2/3Shenzhen People's HospitalNCT04948008Written as IBI306
- Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.CompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT03366688Written as IBI306
Codes
What other systems call tafolecimab · ClinicalTrials.gg INT017102
- UNII (FDA) KV2ZKH0NIMTAFOLECIMABOne source FDA
- NCI Thesaurus C171839TafolecimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KV2ZKH0NIM | TAFOLECIMAB | One source FDA |
| NCI Thesaurus | C171839 | Tafolecimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.